Kornimate/medical-research-clean huggingface dataset:
aripiprazole treatment of bipolar depression

Conditions: Bipolar Depression

Summary: this is a study of addition of aripirazole to the treatment of bipolar depressed patients who are not better on the medications that they are currently receiving.

hypothesis/objectives: aim 1: to investigate whether aripiprazole is effective in the treatment of bipolar depression. hypothesis 1: aripiprazole will lead to a significant decrease in scores on the hamilton depression rating scale (ham-d) during an 8-week treatment course. a. study population: a total number of 10 evaluable patients will be enrolled in the study. c. study design and method this proposal will use an open label design. aripiprazole will be added to the treatment of patients with dsm-iv (american psychiatric association, 1994) bdd. patients will be allowed to continue their psychotropic medication, at a stable dose, as long as they meet inclusion criteria as described below. aripiprazole will be started at a dose of 10 mg for two weeks, 15 mg for an additional two weeks, and 20 mg for the last four weeks. the length of time a patient stays on the maximum dose (20 mg) depends upon the patient's tolerance and treatment response. treatment will continue for 8 weeks with weekly visits and ratings on the 17-item hamilton depression rating scale (ham-d 17) and other ratings scales.

Eligibility criteria:
inclusion criteria: * 1) male or female between 18 - 65 years of age, inclusive 2) satisfy dsm-iv criteria for bipolar disorder depressed phase i.e.,duration of depression \> 2 weeks) 3) no change in psychotropic medication or their doses within 2 weeks of inclusion in the study. 4) inadequately responsive to or intolerant of prior pharmacotherapy as determined by the investigator 5) 17-item hamilton depression rating scale score \> 15 6) young mania rating scale (young, et. al., 1978) (ymrs) \< 10. exclusion criteria: exclusion criteria: 1) history of or currently suffering from serious medical illness, or be on medication that may interact with aripiprazole 2) on any other neuroleptic e.g., olanzapine, risperidone, ziprasidone, haloperidol. 3) history of substance abuse within 3 months or substance dependence within 6 months of the study. 4) pregnant or planning to be pregnant or not using adequate contraception. 5) received electroconvulsive therapy (ect) treatment in the past 1 year. 6) significant suicide or homicide risk at the time of the study; 7) not on any herbal or any other alternative pharmacological treatment. 8) renal or hepatic dysfunction 9) history of decreased sweating or heat stroke. -
early detection of head and neck superficial squamous cell carcinoma in patients with esophagus squamous cell carcinoma

Conditions: Optical Enhancement Endoscopy

Summary: the investigators randomly divide the eligible objects into two groups:1. objects in this group will first receive oe endoscopy observation and subsequent white light imaging(wli) observation during oropharynx and hypopharynx; 2. objects in this group will first receive wli observation and subsequent oe observation during oropharynx and hypopharynx. then, the investigators will compare the detect rate of oropharyngeal and hypopharyngeal superficial squamous cell carcinoma of two groups to find if oe endoscopy can improve the detect rate of oropharyngeal and hypopharyngeal superficial squamous cell carcinoma in esophageal cancer patients.


Eligibility criteria:
inclusion criteria: * order than 18 years old * previous or current histopathological pathology confirmed the presence of esophageal squamous cell carcinoma exclusion criteria: * previously confirmed pharynx/oropharyngeal squamous cell carcinoma * advanced pharynx/hypopharyngeal squamous cell carcinoma * pregnant women and lactating women * pharyngeal or esophageal stenosis, esophageal varices, or active digestive tract hemorrhage influence the observation or fail to obtain pathological diagnosis * previous chemotherapy or radiation therapy affected observation * not completed gastroscopy or refused to take biopsy for various reasons * mental illnesses such as anxiety and depression affect the endoscopic observation * severe systemic disease, can not tolerate gastroscopy * refusal to sign informed consent books
prophylactic antibiotics on urethral catheter withdrawal

Conditions: Urinary Tract Infection; Bacteriuria

Summary: urinary-tract infection (uti) is the most common type of hospital-acquired infection (30% of all). the purpose of this study is to determine whether antibiotic prophylaxis for urinary catheter removal is useful at preventing catheter-associated urinary-tract infection.

urinary-tract infection (uti) is the most common type of hospital-acquired infection (30% of all). the researchers undertake a double-blind, placebo-controlled trial to assess the efficacy of single-dose therapy of trimethoprim-sulfamethoxazole or ciprofloxacin, versus placebo therapy in selected groups of surgical patients who had bladder drainage scheduled to last longer than 3 days.

Eligibility criteria:
inclusion criteria: * urethral catheter in situ for at least 3 days (72h) exclusion criteria: * pregnancy * impaired renal or hepatic function (serum creatinine \> 150 mmol/l, serum transaminases \> 75 iu/l) * fever * symptomatic urinary tract infection * antibiotic use ≤ 48 hours before urinary catheter removal * allergy to trimethoprim-sulfamethoxazole or ciprofloxacin * urologic pathology

Keywords: bacteriuria urinary catheter urinary tract infection prophylaxis urinary catheter removal
comparison of epidural and paracostal catheter placement for pain control after rib fractures

Conditions: Rib Fractures; Wounds and Injuries

Summary: the investigators plan to compare the incidence of successful placement of epidural pain catheters versus paracostal catheters for the control of pain and prevention of pulmonary complications for adult trauma patients with blunt chest wall trauma resulting in multiple rib fractures. when a trauma patient has \> or = to 3 rib fractures on the same side, is being admitted to the surgical icu, and is encountered within 72 hours from the time of their injury, they will be eligible for the study. if they (or a proxy) choose to participate, consent will be obtained and they will randomly be assigned to receive either an epidural or paracostal catheter for pain control. the aim of the study is to determine if paracostal catheters are noninferior to epidurals for controlling pain in multisystem trauma patients. secondarily the investigators will evaluate success and time of placement of the assigned intervention and follow the patient throughout their hospital course to compare the success of analgesia provided by each modality along with any complications and/or benefits of the two types of catheters.


Eligibility criteria:
inclusion criteria: * \>/= 3 rib fractures on a single side * admitted to the surgical icu * recruited within 24 hours of admission exclusion criteria: * patient allergy to local anesthetics * patient refusal * inability to consent for any reason * prisoners * age \< 18 * pregnant women (pregnancy screen performed as part of routine trauma admission labs) * absolute contraindications for either thoracic epidural or paracostal pain catheter placement which include: 1. localized rash or skin infection over the likely site of insertion (we never want to translocate infectious material from the skin to the epidural space or even into the soft tissue where paracostal catheters lay, although for these there is more flexibility in adjusting placement) 2. spinal/vertebral instability/fracture including any significant vertebral body injury and 3 or more spinous process fractures near the level of desired epidural placement (transverse process fractures are not considered a contraindication) 3. history of extensive back surgery at the level of desired epidural placement 4. severe aortic stenosis, mitral stenosis, or pulmonary hypertension 5. inability to correct coagulopathy (to international normalized ratio\>1.5) 6. persistent hemodynamic instability (hypotension with systolic blood pressure\<90 that does not respond to initial fluid boluses and requires ongoing pressors beyond the 72 hour window for enrollment) 7. inability to cooperate and participate in placement (if intubated and sedated, for example) or to lie in the correct position for placement (lateral decubitus for paracostal pain catheters, either sitting up or lateral decubitus for epidural placement) 8. concern for elevated intracranial pressure (we imagine these patients will also be intubated)
in control--hypertension reduction in inner city seattle

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension

Summary: to implement and evaluate with a randomized, controlled trial interventions to improve control of hypertension among inner city low- income and minority residents of seattle.

background: low income residents of inner city seattle especially african americans, have significantly higher rates of cardiovascular mortality and morbidity than other seattle residents. hypertension is a major risk factor for these excess deaths. the prevalence of both hypertension and uncontrolled hypertension is also higher among low income and minority residents, especially young men. the study was in response to a demonstration and education initiative, "improving hypertensive care for inner city minorities", which was reviewed and approved by the clinical applications and prevention advisory committee in april 1992 and by the national heart, lung, and blood advisory council in may 1992. the request for applications was released in october 1992. design narrative: two interventions were studied, both of which improved upon existing activities and strengthened the relationship between community and clinic-based hypertension control activities. the first intervention improved the identification and entry into care of new and uncontrolled hypertensives in the community with an emphasis on bringing more young males (especially african american) through: (a) screening and education activities (b) a microcomputer-based client tracking system to follow persons with elevated blood pressure (c) an outreach system to improve follow-up into clinical care. the second intervention enhanced access to and compliance with hypertension care among patients using the participating clinics (both currently registered patients and new patients referred through community screening activities) through: (a) microcomputer-based patient tracking system at each clinic to identify nonadherent and other high risk patients (b) placing a hypertension patient care coordinator at each clinic who created an individualized care plan for each patient and coordinated a wide range of services, including specific strategies to enhance compliance (c) making available outreach workers to assist in efforts to keep patients in care. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
prp versus ha in osteoarthritis of the patellofemoral joint

Conditions: Patellofemoral Osteoarthritis

Summary: the aim of the study is to compare the 12-month clinical outcomes of patients with patellofemoral osteoarthritis undergoing infiltrative treatment with fresh prp and ha

166 patients affected by patellofemoral osteoarthritis will be included in a double-blinded rct. in this study one group of patients will be treated with 1 intra-articular injection of prp (treatment arm) and one group will be treated with 1 intra-articular injection of ha (control arm). patients will be followed-up with clinical evaluation at baseline and at 2.6.12 and 24 months. questionnaires will be administered for clinical evaluations during the follow-up visits.

Eligibility criteria:
inclusion criteria: 1. age between 30 and 65; 2. signs and symptoms of isolated patellofemoral osteoarthritis present in one or both knees; 3. radiographic signs of isolated patellofemoral osteoarthritis (according to iwano et al stage 1-3 classification) or chondropathy (assessed on mri) with k-l grade of the other compartments ≤ 2. \[pmid: 2302884 - pmid: 27979409\] ; 4. hemoglobin \> 11 g/dl; platelet count \> 150,000 plt/mm3 (recently performed cbc exam); 5. no clinically significant electrocardiographic alterations (recently performed ecg). 6. ability and consent of patients to actively participate in clinical follow-up; 7. signature of informed consent. exclusion criteria: 1. patients unable to express consent; 2. patients who have undergone intra-articular infiltration of another substance within the previous 6 months; 3. patients undergoing knee surgery within the previous 12 months; 4. patients with malignant neoplasms; 5. patients with rheumatic diseases; 6. patients with diabetes; 7. patients with hematologic diseases (coagulopathies); 8. patients on anticoagulant-antiaggregant therapy; 9. patients with thyroid metabolic disorders; 10. patients abusing alcoholic beverages, drugs or medications; 11. body mass index \> 35; 12. patients who have taken nsaids in the 3 days prior to blood draw; 13. patients with cardiovascular disease for which a 60 ml blood draw would be contraindicated; 14. patients with a recently performed blood test with hb\< 11 g/dl and platelets \< 150,000 plt/mm3. 15. previous treatment of patellar dislocation 16. iwano score of grade 4.

Keywords: prp ha osteoarthritis autologous prp prp injection ha injection injection treatment randomized controlled trial hyaluronic acid platelet rich plasma
effects of incentive spirometry with and without aerobic exercises in interstitial lung disease

Conditions: Interstitial Lung Disease

Summary: effects of incentive spirometry with and without aerobic exercises on dyspnea, exercise capacity and quality of life in interstitial lung disease

interstitial lung disease is the large group of diseases most of which cause progressive scarring of lung tissue. the scarring associated with interstitial lung disease eventually affects participants ability to breathe and get enough oxygen into participants bloodstream. this is occurring by the long term work in dusty places or factories randomized control trials will be conducted in dhq hospital layyah through the convent sampling techniques on patients which will be allocated through convenience sampling technique on 32 patients which will be allocated through simple random sampling through sealed opaque enveloped into group a and group b. after the conventional treatment group a will be treated with aerobic exercise and group b will be treated without the aerobic exercise. in group a check the effect of spirometry with aerobic exercise (walking, jogging, running and cycling) and group b check the effect of spirometry without the aerobic exercise and dyspnea by using the 6 mint walk test, borage scale, pft, chest expansions and quality of life questionnaire. investigators apply the aerobic exercise by using the spirometer on the interstitial lung diseases patient and check the effectiveness of dyspnea, exercise capacity and quality of life of the patient. data will be collect by the questioner and data will be analyzed using spss software version 21. after assessing normality of data by shapiro - wilk test, it will be decided either parametric or non-parametric test will be used within a group or between two groups.

Eligibility criteria:
inclusion criteria: * all patients18 to 55 years of age (21) * both gender(m/f) * diagnosed as ild ( sarcoidosis,acute interstitial pneumonia etc.)on clinical, radiological, and histopathological basis * all included patients were clinically stable without exacerbations in the past 1 month. exclusion criteria: * patients with other significant respiratory disorders such as acute infections, pulmonary tuberculosis, copd, asthma, bronchiectasis, lung carcinoma, and pneumothorax * connective tissue disease-associated ild * patients having other co morbid diseases preventing from exercise training, for example, disability due to orthopedic, neurological, and acute cardiac causes * physically and mentally unwell to attend the hospital for training * already completed or participated in a pr program in the past 1 year

Keywords: shortness of breath ,cough,fatigue.
prehabilitation in patients with esophageal or gastric cancers

Conditions: Esophageal Cancer; Gastric Cancer

Summary: objectives: the primary objective of this study is to assess the feasibility of a internet-based preoperative exercise program in patients with esophageal or gastric cancers. secondary objectives are to evaluate the effects of this preoperative program on functional capacity, anxiety and depression, quality of life and fatigue methods: this feasibility study will be conduct at university hospital saint-luc in brussels. twenty patients with esophageal or gastric cancers will participate in internet-based program 3 sessions per week. each session will combine aerobic and resistance training. moreover, inspiratory muscle strengthening (imt) will be performed daily. the researcher will conduct weekly telephone calls to educate and motivate subjects. assessments will be performed at baseline, one day before surgery, 1 month and 3 months after surgery. the following parameters will be measured: functional capacity, quality of life, fatigue, anxiety and depression.


Eligibility criteria:
inclusion criteria: * diagnosis of esophageal cancer or gastric cancer requiring surgery * more than 18 years * able to read, write and understand french or english * time before surgery \> 2 weeks exclusion criteria: * surgical emergency * cognitive or neuropsychiatric diseases * neuromuscular or orthopedic disorders limiting exercises * cardiopulmonary disease contraindicating exercises
tuberculosis research blood bank

Conditions: Tuberculosis

Summary: to create a tuberculosis research blood bank for future molecular genetics and serological studies


Eligibility criteria:
inclusion criteria: * tb suspect with positive sputum smear
mri screening of second primary cancer occurring within radiation fields after treatment by external beam radiation therapy for hereditary retinoblastoma (depiscarrh)

Conditions: Hereditary Retinoblastoma

Summary: the purpose of this study is to assess the benefit of mr screening for asymptomatic head \& neck (or cns) second primary cancers occurring in hereditary retinoblastoma patients previously treated by external beam radiation therapy (ebrt).

patients with hereditary retinoblastoma treated during infancy by external beam radiation therapy (ebrt) the risk of second primary cancer occurring within radiation fields is high. the aim of this study is to depict by mri secondary tumors as early as possible, before the occurrence of clinical symptoms. affected patients will be further managed in a national expert center with dedicated diagnostic and treatment procedures. however, the benefit of such management has to be assessed in terms of prognosis.

Eligibility criteria:
inclusion criteria: * personal history of hereditary retinoblastoma (i.e., familial history of retinoblastoma, or bilateral retinoblastoma, or unilateral multifocal retinoblastoma, or identified germline rb1 mutation or 13q deletion) * external beam radiation therapy (ebrt) used for retinoblastoma treatment * age at inclusion greater or equal to 7 years old. * time period between the end of ebrt and inclusion date of 5 years or more * written informed consent signed by patient (or legal representative) exclusion criteria: * personal history of non-familial unilateral unifocal retinoblastoma without rb1 germline mutation. * personal history of second primary neoplasm occurring within radiation fields * contraindication for mri (pacemaker, intraocular metallic foreign body, defibrillators or other implanted electronic devices, intracranial ferro-magnetic clips) or associated conditions preventing from mr examination (intraocular prostheses and implants are not a contraindication for mri; orthodontic metallic devices are not a contraindication but might decrease the image quality and should be removed, if possible) * patients unable to comply with follow-up study requirements, for any geographical, social or psychological reason

Keywords: hereditary retinoblastoma, external beam radiation therapy (ebrt)
efficacy of sana treatment in fibromyalgia

Conditions: Fibromyalgia

Summary: the purpose of this research study is to evaluate the effectiveness of an experimental device called the sana pain reliever device (sana device) on treating pain due to fibromyalgia.


Eligibility criteria:
inclusion criteria: * willing to and capable of providing written informed consent prior to the conduct of any study-related procedures. * male or female, 18 to 65 years of age, inclusive. * clinical diagnosis of fibromyalgia given a minimum of 8 weeks prior to screening. * patient must have an average pain severity score of ≥40 and \<90 on the 100-point vas for the last 72 hours prior to screening. * any analgesic therapy must be at approximately stable levels for at least 14 days prior to enrollment and remain steady throughout the study. * willing and able to comply with the study requirements, complete study assessments, and participate at scheduled times for the duration of the treatment phase. * able to understand, speak and read english sufficient for the completion of study assessments. exclusion criteria: * pregnant or lactating females as self-reported. * history or presence of photo-sensitive epilepsy or other photo-sensitive conditions. * history or presence of condition(s) that may affect balance, such as seizure disorders or vertigo. * diagnosis of cancer or active cancer treatment occurring within the last year. * surgery or trauma requiring rehabilitation within the last 12 weeks. * vision impairments that affect perception of light, color, or brightness in one or both eyes, and differences in visual perception between eyes, at the discretion of the investigator. * deafness in one or both ears, perceived differences in hearing between ears, or tinnitus, at the discretion of the investigator. * current ear or eye infection, untreated allergies, or acute illness that may affect eyes or hearing (e.g., due to congestion). * presence of inflammation or broken skin around the eyes in the area of the mask. * presence of narcolepsy or untreated sleep apnea or requiring treatment for sleep apnea such that use of device at bedtime will be interrupted, at discretion of the investigator. * participation in any other clinical study in which medication(s) are being delivered or have used an investigational drug or device within the last 30 days. * any pending legal action that could prohibit participation or compliance in the study. * recent history of or current evidence of suicidal ideation or active suicidal behavior, based on medical history, at the discretion of the investigator. * significant medical conditions or other circumstances which, in the opinion of the investigator, would preclude compliance with the protocol, adequate cooperation in the study or obtaining informed consent, or may prevent the patient from safely participating in study.